|
1
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidmeiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kew MC: Hepatocellular carcinoma:
Epidemiology and risk factors. J Hepatocellular Carcinoma.
1:115–125. 2014. View Article : Google Scholar
|
|
4
|
Chen K and Rajewsky N: The evolution of
gene regulation by transcription factors and microRNAs. Nat Rev
Genet. 8:93–103. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY,
Zhang JF, Shen HB, Zhang CY and Zen K: Serum microRNA profiles
serve as novel biomarkers for HBV infection and diagnosis of
HBV-positive hepatocarcinoma. Cancer Res. 70:9798–9807. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wong QW, Lung RW, Law PT, Lai PB, Chan KY,
To KF and Wong N: MicroRNA-223 is commonly repressed in
hepatocellular carcinoma and potentiates expression of stathmin1.
Gastroenterology. 135:257–269. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bhattacharya S, Steele R, Shrivastava S,
Chakraborty S, Di Bisceglie AM and Ray RB: Serum miR-30e and
miR-223 as novel noninvasive biomarkers for hepatocellular
carcinoma. Am J Pathol. 186:242–247. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ramkissoon SH, Mainwaring LA, Ogasawara Y,
Keyvanfar K, McCoy JP Jr, Sloand EM, Kajigaya S and Young NS:
Hematopoietic-specific microRNA expression in human cells. Leuk
Res. 30:643–647. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fazi F, Racanicchi S, Zardo G, Starnes LM,
Mancini M, Travaglini L, Diverio D, Ammatuna E, Cimino G, Lo-Coco
F, et al: Epigenetic silencing of the myelopoiesis regulator
microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell. 12:457–466.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jia CY, Li HH, Zhu XC, Dong YW, Fu D, Zhao
QL, Wu W and Wu XZ: miR-223 suppresses cell proliferation by
targeting IGF-1R. PLoS One. 6:e270082011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li G, Cai M, Fu D, Chen K, Sun M, Cai Z
and Chen B: Heat shock protein 90B1 plays an oncogenic role and is
a target of microRNA-223 in human osteosarcoma. Cell Physiol
Biochem. 30:1481–1490. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lu TX, Lim E, Besse JA, Itskovich S,
Plassard AJ, Fulkerson PC, Aronow BJ and Rothenberg ME: miR-223
deficiency increases eosinophil progenitor proliferation. J
Immunol. 190:1576–1582. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jung HJ and Suh Y: Regulation of IGF-1
signaling by microRNAs. Front Genet. 5:4722015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fürstenberger G and Senn H: Insulin-like
growth factors and cancer. Lancet Oncol. 3:298–302. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Martini M, De Santis M, Braccini L,
Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An
updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Samani A, Yakar S, LeRoith D and Brodt P:
The role of the IGF system in cancer growth and metastasis:
Overview and recent insights. Endocr Rev. 28:20–47. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu J, Wu C, Che X, Wang L, Yu D, Zhang T,
Huang L, Li H, Tan W, Wang C and Lin D: Circulating MicroRNAs,
miR-21, miR-122, and miR-223, in patients with hepatocellular
carcinoma or chronic hepatitis. Mol Carcinog. 50:136–142. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nian W, Ao X, Wu Y, Huang Y, Shao J, Wang
Y, Chen Z, Chen F and Wang D: miR-223 functions as a potent tumor
suppressor of the Lewis lung carcinoma cell line by targeting
insulin-like growth factor-1 receptor and cyclin-dependent kinase
2. Oncol Lett. 6:359–366. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu L, Li H, Jia CY, Cheng W, Yu M, Peng M,
Zhu Y, Zhao Q, Dong YW, Shao K, et al: MicroRNA-223 regulates FOXO1
expression and cell proliferation. FEBS Lett. 586:1038–1043. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Reidy-Lagunes DL, Vakiani E, Segal MF,
Hollywood EM, Tang LH, Solit DB, Pietanza MC, Capanu M and Saltz
LB: A phase 2 study of the insulin-like growth factor-1 receptor
inhibitor MK-0646 in patients with metastatic, well-differentiated
neuroendocrine tumors. Cancer. 118:4795–4800. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pitts TM, Tan AC, Kulikowski GN, Tentler
JJ, Brown AM, Flanigan SA, Leong S, Coldren CD, Hirsch FR,
Varella-Garcia M, et al: Development of an integrated genomic
classifier for a novel agent in colorectal cancer: Approach to
individualized therapy in early development. Clin Cancer Res.
16:3193–3204. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Masciarelli S, Fontemaggi G, Di Agostino
S, Donzelli S, Carcarino E, Strano S and Blandino G:
Gain-of-function mutant p53 downregulates miR-223 contributing to
chemoresistance of cultured tumor cells. Oncogene. 33:1601–1608.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gusscott S, Kuchenbauer F, Humphries RK
and Weng AP: Notch-mediated repression of miR-223 contributes to
IGF1R regulation in T-ALL. Leuk Res. 36:905–911. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li S, Li Z, Guo F, Qin X, Liu B, Lei Z,
Song Z, Sun L, Zhang HT, You J and Zhou Q: miR-223 regulates
migration and invasion by targeting Artemin in human esophageal
carcinoma. J Biomed Sci. 18:242011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li X, Zhang Y, Zhang H, Liu X, Gong T, Li
M, Sun L, Ji G, Shi Y, Han Z, et al: miRNA-223 promotes gastric
cancer invasion and metastasis by targeting tumor suppressor
EPB41L3. Mol Cancer Res. 9:824–833. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Laios A, O'Toole S, Flavin R, Martin C,
Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, et al:
Potential role of miR-9 and miR-223 in recurrent ovarian cancer.
Mol Can. 7:352008. View Article : Google Scholar
|
